Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2012 Dec;20(12):3355-64.
doi: 10.1007/s00520-012-1492-x. Epub 2012 May 15.

Taxane-induced peripheral neuropathy and health-related quality of life in postoperative breast cancer patients undergoing adjuvant chemotherapy: N-SAS BC 02, a randomized clinical trial

Kojiro Shimozuma  1 , Yasuo Ohashi, Ayano Takeuchi, Toshihiko Aranishi, Satoshi Morita, Katsumasa Kuroi, Shozo Ohsumi, Haruhiko Makino, Noriyuki Katsumata, Masaru Kuranami, Kimito Suemasu, Toru Watanabe, Frederick H Hausheer
Affiliations
Randomized Controlled Trial

Taxane-induced peripheral neuropathy and health-related quality of life in postoperative breast cancer patients undergoing adjuvant chemotherapy: N-SAS BC 02, a randomized clinical trial

Kojiro Shimozuma et al. Support Care Cancer. 2012 Dec.

Abstract

Purpose: To elucidate whether adjuvant taxane monotherapy is a feasible and tolerable for postoperative breast cancer patients, we evaluated the severity of chemotherapy-induced peripheral neuropathy (CIPN) and the relative tolerability of regimens by health-related quality of life (HRQOL) assessment in node-positive breast cancer patients treated with taxane-containing regimens.

Methods: We evaluated CIPN and HRQOL in the first 300 patients enrolled in a larger (1,060 total) multicenter phase III trial randomized to one of four adjuvant regimens: (1) anthracycline-cyclophosphamide followed by paclitaxel (ACP), (2) AC followed by docetaxel (ACD), (3) paclitaxel alone (PTX), or (4) docetaxel alone (DTX). CIPN was assessed by the Patient Neurotoxicity Questionnaire (PNQ) and the National Cancer Institute Common Toxicity Criteria, and HRQOL by Functional Assessment of Cancer Therapy-General (FACT-G). CIPN and HRQOL scores were compared between ACP and ACD vs. PTX and DTX, and ACP and PTX vs. ACD and DTX.

Results: PNQ sensory scores were significantly higher in patients treated with taxane monotherapy compared to treatment with AC followed by taxane (P = .003). No significant differences in PNQ sensory scores were observed between the ACP and PTX vs. ACD and DTX regimens (P = .669). Regardless of taxane regimen, PNQ severity scores for CIPN appear to be largely reversible within 1 year of adjuvant treatment. No significant difference in FACT-G scores was observed between any regimens during the study treatments.

Conclusions: Patient-reported CIPN was significantly more severe with single-agent adjuvant taxane compared to AC followed by taxane treatment; however, the HRQOL findings support that single-agent taxane treatment is tolerable.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Support Care Cancer. 2009 Dec;17(12):1483-91 - PubMed
    1. J Clin Oncol. 2005 Aug 20;23(24):5542-51 - PubMed
    1. Cochrane Database Syst Rev. 2007 Oct 17;(4):CD004421 - PubMed
    1. Ann Oncol. 2000 May;11(5):509-13 - PubMed
    1. Ann Oncol. 1998 Jul;9(7):739-44 - PubMed

Publication types

MeSH terms

LinkOut - more resources